Iyas Daghlas: DOACs Use, Genetic Reduction of Coagulation Factors and Risk of Cerebral Venous Thrombosis
Iyas Daghlas, Vascular Neurology Fellow and Stroke Researcher at the University of California, shared on LinkedIn about a recent article he and his colleagues co-authored, adding:
”Excited to share our new publication in Neurology: ‘Direct Oral Anticoagulant Protein Targets and Risk of Cerebral Venous Thrombosis: A Mendelian Randomization Study.’
Cerebral venous thrombosis (CVT) is a rare form of stroke treated with anticoagulation.
Despite widespread off-label direct oral anticoagulant (DOAC) use, no adequately powered RCT has demonstrated DOAC efficacy, and many patients continue to be treated with warfarin, which carries substantial major bleeding risk.
We addressed this evidence gap by examining effects of naturally randomized genetic variants perturbing the protein targets of established (F2+F10) and emerging (F11) DOACs.
See Table 1 for a cool demonstration of the natural allocation of covariates/confounders across genotypes, mimicking an RCT ‘Table 1.’
We found evidence that genetically reduced levels of thrombin, factor Xa, and factor XI are associated with reduced CVT risk – see forest plot!
What this means:
- FXI inhibitors (milvexian, asundexian, etc) are among the most actively investigated therapeutic targets in thrombosis today, with multiple Phase III trials underway. Our data provide the first human genetic evidence supporting repurposing potential for CVT, a new indication for this drug class.
- Human genetics supports efficacy for established DOAC protein targets (thrombin and factor Xa) in reducing CVT risk
- These data support the notion that, in general, therapeutics that are effective for venous thromboembolism will likely also work for CVT
Appreciate collaborators Marta Pérez Alcántara and Dipender Gill!”
Title: Direct Oral Anticoagulant Protein Targets and Risk of Cerebral Venous Thrombosis. A Mendelian Randomization Study
Authors: Iyas Daghlas, Marta Pérez Alcántara, Dipender Gill
Read the Full Article on Neurology
Stay updated on all scientific advances with Hemostasis Today.
-
Jul 30, 2026, 18:36Amina Ammar: Evaluating Rivaroxaban Dosing Alignment Across Cockcroft–Gault and eGFR Equations
-
Jul 30, 2026, 18:11Tobias Tritschler: Evaluating Timing, Translation and Preparedness in COVID-19 Anticoagulation Management
-
Jul 30, 2026, 16:05Peter Zdziarski: Today is Chronic Disease Awareness Day
-
Jul 30, 2026, 15:50Ahmad Gharehbaghian: New Blood Transfusion Centers Open in Iran
-
Jul 30, 2026, 15:32Can We Better Protect Hospitalized Patients With Obesity From Venous Thromboembolism? – RPTH Journal
-
Jul 30, 2026, 15:162025 Platelet Transfusion Thresholds: When to Transfuse and When Not to Transfuse – Chokri Ben Lamine
-
Jul 30, 2026, 14:34Flora Peyvandi: Genetics of Early-Onset Coronary Artery Disease in Iranians
-
Jul 30, 2026, 14:22Stéphanie Forté: New Evidence Strengthens the Case for Hydroxyurea in HbSC Disease
-
Jul 30, 2026, 14:09Hilal Ahmad: New Guidelines for Pediatric Ischemic Stroke Management